




Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297019	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: WHOLE BLOOD-EDTA	Report Date	: 15/Oct/2021 11: 51AM


HAEMATOLOGY

GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
Hemogram				
Hemoglobin	11.9	g/dL	13.0-17.0	Cyanide-free SLS-Hemoglobin
RBC	3.82	mili/cu.mm	4.5 - 5.5	DC Impedence Method
HCT	39.2	%	40 - 50	RBC pulse height detection
MCV	102.6	fl	83 - 101	Calculated
MCH	31.2	pg	27 - 32	Calculated
MCHC	30.4	g/dL	31.5 - 34.5	Calculated
RDW-SD	54.0	fl	39-46	Calculated
RDW-CV	14.1	%	11.5-14	Calculated
Total Leucocyte Count	7.0	10 ³ /μl	4 - 10	Flowcytometry/Microscopy
Differential Leucocyte Count				
Neutrophils	69.6	%	40-80	Flowcytometry/Microscopy
Lymphocytes	18.1	%	20-40	Flowcytometry/Microscopy
Monocytes	7.8	%	2-10	Flowcytometry/Microscopy
Eosinophils	2.8	%	1-6	Flowcytometry/Microscopy
Basophils	1.7	%	0-2	Flowcytometry/Microscopy
Absolute Leucocyte Count				
Absolute Neutrophil Count	4.89	10 ³ /μl	2-7	Calculated
Absolute Lymphocyte Count	1.27	10 ³ /μl	1-3	Calculated
Absolute Monocyte Count	0.55	10 ³ /μl	0.2-1	Calculated
Absolute Eosinophil Count	0.2	10 ³ /μl	0.02-0.5	Calculated
Absolute Basophil Count	0.12	10 ³ /μl	0.02-0.1	Calculated
Platelet Count	274	10 ³ /μl	150-410	Electrical Impedence/Microscopy
MPV	10.3	fl	6.5 - 12	Calculated
PDW	12	fl		Calculated

Kindly correlate clinically
 Results relate only to the sample, as received


 Dr. Dinesh Kumar
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Dhananjay Singh
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Nitika Vashisht
 MBBS, MD(Pathology)
 Consultant Pathologist





Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297019	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: WHOLE BLOOD-EDTA	Report Date	: 15/Oct/2021 04: 16PM

BIOCHEMISTRY

GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
Glycosylated Hemoglobin				
Glycosylated Hemoglobin (HbA1c)	8.1	%	4 - 5.6	HPLC
Estimated average glucose (eAG)	185.77	mg/dL		Calculated

Comment:

Interpretation:

HbA1c%

≤ 5.6	Normal
5.7 - 6.4	At Risk For Diabetes
≥ 6.5	Diabetes

Adapted from American Diabetes Association.

Comments:-

A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise & recent food intake. Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.


Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.


Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the HbA1c result does not correlate with the patient's blood glucose levels.

- HPLC - High performance liquid chromatography

Kindly correlate clinically
 Results relate only to the sample, as received


 Dr. Dinesh Kumar
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Dhananjay Singh
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Nitika Vashisht
 MBBS, MD(Pathology)
 Consultant Pathologist





Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297018	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: Serum	Report Date	: 15/Oct/2021 06: 05PM

BIOCHEMISTRY

GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
Iron Studies, Basic				
Iron Serum	57	µg/dL	65-175	Ferene
Total Iron Binding Capacity (TIBC)	264.75	ug/dL	134 - 415	Calculated
Transferrin Saturation	21.53	%	16-50	Calculated
Unsaturated Iron Binding Capacity	207.75	ug/dl	69 - 240	Ferene

Comment:


Iron is an essential trace mineral element which forms an important component of hemoglobin, metallocompounds and Vitamin A. Deficiency of iron is seen in iron deficiency and anaemia of chronic disorders. Increased iron concentration are seen in hemolytic anaemias, hemochromatosis and acute liver disease. Serum Iron alone is unreliable due to considerable physiologic diurnal variation in the results with highest values in the morning and lowest values in the evening as well as variation in response to iron therapy .


Total Iron Binding capacity (TIBC) is a direct measure of the protein Transferrin which transports iron from the gut to storage sites in the bone marrow. Increased levels of TIBC suggest that total iron body stores are low, increased concentration may be the sign of Iron deficiency anaemia, polycythemia vera ,and may occur during the third trimester of pregnancy. Decreased levels may be seen in hemolytic anaemia, hemochromatosis, chronic liver disease, hypoproteinemia ,malnutrition.

Unsaturated Iron Binding Capacity (UIBC) is increased in low iron state and decreased in high iron concentration such as hemochromatosis. In case of anaemia of chronic disease the patient may be anaemic but has adequate iron reserve and a low uIBC.

Transferrin Saturation occurs in Idiopathic hemochromatosis and Transfusional hemosiderosis where no unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of Transferrin.

Kindly correlate clinically
 Results relate only to the sample, as received


 Dr. Dinesh Kumar
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Dhananjay Singh
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Nitika Vashisht
 MBBS, MD(Pathology)
 Consultant Pathologist





Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297018	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: Serum	Report Date	: 15/Oct/2021 06: 05PM

BIOCHEMISTRY


GOOD HEALTH PACKAGE


Test Name	Result	Unit	Bio. Ref. Range	Method
Lipid Profile				
Cholesterol	136	mg/dL	Desirable <200, Borderline High 200 - 239, High >=240	Enzymatic
Triglycerides	121	mg/dL	Normal: < 150, Borderline: 150 - 199, High:200 - 499, Very High >=500	Glycerol Phosphate Oxidase
HDL Cholesterol	38	mg/dL	40 - 60	Accelerator Selective Detergent
LDL Cholesterol	73.89	mg/dl	Desirable: <100 Above desirable: 100 - 129 Borderline high : 130 - 159 High : 160 - 189 Very high : >=190	Calculated
VLDL Cholesterol	24	mg/dl	10.0-30.0	Calculated
Cholesterol : HDL Cholesterol	3.6	Ratio		Calculated
HDL/LDL Ratio	0.52	Ratio		Calculated
LDL/HDL Ratio	1.94	Ratio		Calculated
Non-HDL Cholesterol	98.12	mg/dl	Desirable:< 130, Above Desirable:130 - 159, Borderline High:160 - 189, High:190 - 219, Very High: >= 220	Calculated

Comment:

In all adults (>=20 years of age), a fasting lipoprotein profile should be obtained at least every 5 years. The measurement and monitoring of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy. An elevated level of cholesterol

Kindly correlate clinically
Results relate only to the sample, as received


Dr. Dinesh Kumar
MBBS, MD(Pathology)
Consultant Pathologist


Dr. Dhananjay Singh
MBBS, MD(Pathology)
Consultant Pathologist


Dr. Nitika Vashisht
MBBS, MD(Pathology)
Consultant Pathologist






Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297018	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: Serum	Report Date	: 15/Oct/2021 06: 05PM


BIOCHEMISTRY

GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
<p>carried by circulating apolipoprotein B-containing lipoproteins (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most clinical atherosclerotic cardiovascular disease (ASCVD) events.</p> <p>Reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug therapies.</p> <p>Atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore, both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-reduction therapies.</p> <p>Nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes mellitus.</p>				

Kindly correlate clinically
Results relate only to the sample, as received


Dr. Dinesh Kumar
MBBS, MD(Pathology)
Consultant Pathologist


Dr. Dhananjay Singh
MBBS, MD(Pathology)
Consultant Pathologist


Dr. Nitika Vashisht
MBBS, MD(Pathology)
Consultant Pathologist





Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297018	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: Serum	Report Date	: 15/Oct/2021 06: 05PM

BIOCHEMISTRY

GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
Liver Function Test				
Bilirubin-Total	0.4	mg/dL	0.2-1.2	Diazo
Bilirubin-Direct	0.2	mg/dL	0-0.5	Colorimetric, Diazo Dye
Bilirubin-Indirect	0.2	mg/dL	0.1-1	Calculated
Protein, Total	6.4	g/dL	6.0-8.1	Biuret
Albumin	3.72	g/dL	3.2-4.6	Bromocresol Green
Globulin	2.7	g/dl	1.8 - 3.6	Calculated
A/G Ratio	1.4	Ratio		Calculated
Aspartate Aminotransferase (SGOT)	18	U/L	5-34	NADH w/o P-5'-P
Alanine Transaminase (SGPT)	19	U/L	5-55	NADH w/o P-5'-P
SGOT/SGPT	0.95	Ratio		Calculated
Alkaline Phosphatase	74	U/L		Para-nitrophenyl phosphate
Gamma Glutamyltransferase (GGT)	15	U/L	12-64	L-gamma-glutamyl-3-Carboxy-4-Nitroanilide

Comment:

LFTS are based upon measurements of substances released from damaged hepatic cells into the blood that gives idea of the Existence, Extent and Type of Liver damage.

- Acute Hepatocellular damage: ALT & AST levels are sensitive index of hepatocellular damage
- Obstruction to the biliary tract,Cholestasis and blockage of bile flow:

1) Serum Total Bilirubin concentration 2) Serum Alkaline Phosphatase (ALP) activity 3) Gamma Glutamyl Transpeptidase (GGTP) 4) 5'-Nucleotidase

- Chronic liver disease: Serum Albumin concentration

Bilirubin results from the enzymatic breakdown of heme. Jaundice is a yellowish discoloration of the skin and mucous membranes caused by hyperbilirubinemia.

Pre-hepatic or hemolytic jaundice - Abnormal red cells, antibodies,drugs and toxins,Hemoglobinopathies, Gilbert's syndrome, Crigler-Najjar syndrome


Hepatic or Hepatocellular jaundice-Viral hepatitis,toxic hepatitis, intrahepatic cholestasis


Post-hepatic jaundice -Extrahepatic cholestasis, gallstones, tumors of the bile duct, carcinoma of pancreas

In viral hepatitis and other forms of liver disease associated with acute hepatic necrosis, serum AST and ALT concentrations are elevated even before the clinical signs and symptoms of disease appear. ALT is the more liver-specific enzyme and elevations of ALT activity persist longer than AST activity. Peak values of aminotransferase activity occur between the seventh and twelfth days. Activities then

Kindly correlate clinically

Results relate only to the sample, as received


Dr. Dinesh Kumar
MBBS, MD(Pathology)
Consultant Pathologist


Dr. Dhananjay Singh
MBBS, MD(Pathology)
Consultant Pathologist


Dr. Nitika Vashisht
MBBS, MD(Pathology)
Consultant Pathologist






Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297018	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: Serum	Report Date	: 15/Oct/2021 06: 05PM


BIOCHEMISTRY

GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
<p>gradually decrease, reaching normal activities by the third to fifth week. Peak activities bear no relationship to prognosis and may fall with worsening of the patient's condition.</p> <p>Aminotransferase activities observed in cirrhosis vary with the status of the cirrhotic process and range from the upper reference limit to four to five times higher, with an AST/ALT ratio greater than 1. The ratio's elevation can reflect the grade of fibrosis in these patients. Slight or moderate elevations of both AST and ALT activities have been observed after administration of various medications and chronic hepatic injury such as (1) hemochromatosis, (2) Wilson disease, (3) autoimmune hepatitis, (4) primary biliary cirrhosis, (5) sclerosing cholangitis, and (6) a1-antitrypsin deficiency. AST activity also is increased in acute myocardial infarction, progressive muscular dystrophy and dermatomyositis, reaching concentrations up to eight times the upper reference limit. Slight to moderate AST elevations are noted in hemolytic disease.</p> <p>GGT is a sensitive indicator of the presence of hepatobiliary disease, being elevated in most subjects with liver disease regardless of cause. Increased concentrations of the enzyme are also found in serum of subjects receiving anticonvulsant drugs, such as phenytoin and phenobarbital.</p>				

Kindly correlate clinically
 Results relate only to the sample, as received


 Dr. Dinesh Kumar
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Dhananjay Singh
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Nitika Vashisht
 MBBS, MD(Pathology)
 Consultant Pathologist





Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02:35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06:33AM
Barcode ID	: A4297018	Sample Receive Date	: 15/Oct/2021 08:44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: Serum	Report Date	: 15/Oct/2021 06:05PM

BIOCHEMISTRY

GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
Kidney Panel with GFR				
Blood Urea Nitrogen	23.90	mg/dL	8.4 - 25.7	Urease
Urea	51.15	mg/dL	17.97-54.99	Calculated
Creatinine	1.83	mg/dL	0.72 - 1.25	Jaffe mod./Picrate
BUN/Creatinine Ratio	13.1	Ratio		Calculated
Calcium	8.5	mg/dL	8.8-10.0	Arsenazo III complex
Uric Acid	5.8	mg/dL	3.5-7.2	Uricase
Glomerular Filtration Rate	37.58	mL/min/1.73m2		Calculated

Interpretation:-

Age in years GFR in mL/min/1.73m2

20 - 29	116
30 - 39	107
40 - 49	99
50 - 59	93
60 - 69	85
>=70	75

NOTE:-

* National Kidney Disease Education program recommends the use of MDRD equation to estimate or predict GFR in adults (>=20 years) with chronic Kidney Disease (CKD).

* MDRD equation is most accurate for GFR <=60 mL/min/1.73m2

* Recalculation of estimated GFR is required for African American race.


CKD Stage	Description	GFR (mL/min/1.73m2)	Associated Findings
0	Normal Kidney Function	>90	No proteinuria
1	Kidney damage with normal or high GFR	>90	Presence Protein, Albumin, cells or casts seen in urine
2	Mild decrease in GFR	60 - 89 -	
3	Moderate decrease in GFR	30 - 59 -	
4	Severe decrease in GFR	15 - 29 -	
5	Kidney Failure	<15 -	


Comments :-

Modification of diet in renal disease (MDRD) equation is most thoroughly validated an superior to all the other method for estimation of GFR. It does not require weight as a variable and yields an estimated GFR normalized to 1.73m2 body surface area. Using serum creatinine alone gives a poor inference of GFR because

Kindly correlate clinically

Results relate only to the sample, as received


Dr. Dinesh Kumar
MBBS, MD(Pathology)
Consultant Pathologist


Dr. Dhananjay Singh
MBBS, MD(Pathology)
Consultant Pathologist


Dr. Nitika Vashisht
MBBS, MD(Pathology)
Consultant Pathologist







Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297018	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: Serum	Report Date	: 15/Oct/2021 06: 05PM

BIOCHEMISTRY
GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
they are inversely related and effects of age, sex and race on creatinine production complicate interpretation. For African races a modified formula is used for calculation of GFR.				

Kindly correlate clinically
 Results relate only to the sample, as received


 Dr. Dinesh Kumar
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Dhananjay Singh
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Nitika Vashisht
 MBBS, MD(Pathology)
 Consultant Pathologist





Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297018	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: Serum	Report Date	: 15/Oct/2021 05: 48PM

Immunology

GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
Thyroid profile Total				
Thyroid Profile				
T3, Total	0.57	ng/mL	0.35-1.93	CMIA
T4, Total	9.0	µg/dL	4.87-11.72	CMIA
Thyroid Stimulating Hormone - Ultra Sensitive	0.63	µIU/mL	0.35-4.94	CMIA

Comment:

Thyroid dysfunction is common in the general population and Laboratory tests are essential for the accurate diagnosis and cost-effective monitoring of thyroid dysfunction. TSH is now firmly established as the first-line thyroid function test to assess thyroid status for most clinical conditions. Interpretation of the results of thyroid function tests is facilitated by an understanding of thyroid hormone physiology, especially the normal inverse relationship between free T₄ and TSH concentrations. Changes in thyroid status are normally associated with concordant changes in T₃, T₄ and TSH concentrations (e.g. raised T₄ and T₃ with suppressed TSH in thyrotoxicosis; low T₄ and T₃ with elevated TSH in hypothyroidism). An abnormal TSH requires further investigation, including measurement of free T₄. In most clinical situations involving discordant FT₄ and TSH results, the TSH test usually yields the most diagnostically reliable result, provided that the patient is not receiving medications that directly inhibit TSH secretion, and there are no conditions affecting the pituitary-thyroid axis.. Using TSH as a single criterion has been shown to accurately classify the thyroid state of a patient in over 95% of cases. Non-thyroidal illness (NTI), pituitary disease and various drugs can all affect the axis and cause discrepancies between TSH levels, thyroid hormone levels and the clinical state. Measurement of the TSH level is indicated for patients with symptoms suggestive of thyroid dysfunction, reduced bone mineral density, dyslipidaemia, depression, or atrial fibrillation.

Total T₄ measures the total amount of thyroxine circulating in the bloodstream. Indications: Used to make diagnosis of underactive or overactive thyroid when TSH is abnormal • Used with TSH for monitoring patients with Graves' disease • Newborn screening test for hypothyroidism • Fairly accurate in patients with no protein abnormalities and not pregnant Free T₄ measures the available, unbound amount of thyroxine in the bloodstream.

Free T₄ is critical for evaluating patients with hypothalamic-pituitary disease. It is also useful for evaluating the response to levothyroxine in cases of poor compliance and in the first months of treating patients with chronic, severe hypothyroidism.


The total T₃ test measures the total amount of triiodothyronine circulating in the bloodstream. Free T₃ measures the free, unbound levels of the hormone triiodothyronine available for use by the body. Total T₃ measurements, however, should be performed in patients suspected of having T₃ thyrotoxicosis and in patients taking drugs that inhibit the peripheral conversion of T₄ to T₃ (such as dexamethasone, propranolol, propylthiouracil, amiodarone, and iodine-containing contrast media)


Maternal hypothyroidism causes adverse effects on fetal psychomotor development, highlighting the significance of evaluating thyroid function during pregnancy. Tests should be performed pre-pregnancy or in the first trimester with TSH tests that can detect mild thyroid failure. During pregnancy, the total levels of T₃ and T₄ are high because of increased TBG, and free T₄ levels may slightly increase during the first trimester but will subsequently decline in the second and third trimesters.

Kindly correlate clinically

Results relate only to the sample, as received




 Dr. Dinesh Kumar
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Dhananjay Singh
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Nitika Vashisht
 MBBS, MD(Pathology)
 Consultant Pathologist



Name	: Mr.OM PRAKASH GOYAL	Order ID	: 3509681
Age/Gender	: 85/Male	Registration Date	: 14-Oct-21 02: 35 PM
Patient ID	: 1MG3445	Collection Date	: 14/Oct/2021 06: 33AM
Barcode ID	: A4297018	Sample Receive Date	: 15/Oct/2021 08: 44AM
Referred By	: SELF	Report Status	: Final Report
Sample Type	: Serum	Report Date	: 15/Oct/2021 05: 48PM


Immunology


GOOD HEALTH PACKAGE

Test Name	Result	Unit	Bio. Ref. Range	Method
<p>In addition to the pre-analytical factors, potential analytical factors that interfere with the thyroid function tests assays such as heterophilic antibodies and autoantibodies, may lead to discordant thyroid function test results. The optimal use of thyroid function tests should be patient-specific and depends on the patient's specific thyroid disease, the stage of the disease and co-existing medical conditions. Results should be interpreted in the appropriate clinical context of the individual patient with good communication between clinicians and the requesting test laboratory.</p>				

*** End Of Report ***

Kindly correlate clinically
 Results relate only to the sample, as received


 Dr. Dinesh Kumar
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Dhananjay Singh
 MBBS, MD(Pathology)
 Consultant Pathologist


 Dr. Nitika Vashisht
 MBBS, MD(Pathology)
 Consultant Pathologist



Conditions of Laboratory Testing & Reporting:

- Test result released pertain to the sample, as received
- Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the interpreting clinician.
- Result delays may happen because of unforeseen or uncontrollable circumstances.
- Test report may vary depending on the assay method used
- Test results may show inter-laboratory variations
- Test results are not valid for medico-legal purposes
- Please mail your queries related to test results to Customer Care mail id cs.labs@1mg.com .

Why Do Preventive Test?

Reality Check



60%

deaths are due to preventable diseases



50%

are at risk of heart disease



59

The mean age of heart failure patients in India



68%

Urban Indians do not practice preventive healthcare



20%

Population suffers from one of the preventable diseases



50 million

people in India suffer from diabetes, making it the Diabetes Capital of the World.

Average cost per case of hospitalisation in urban India is **`26,455**

How much does it cost you to avoid getting sick?

`1 spent on prevention saves `133 on absenteeism cost and

`6.62 in healthcare costs.

Prevent illness instead of treating them!

Comprehensive Full Body Check-up (105 tests)

Contains tests of Liver, Kidney, Heart, Vitamins, Diabetes, etc.

Women Wellness Package

(35 tests)

Contains tests of thyroid, hormones, Iron studies etc.

All laboratory results, investigations and adjuvant information are subject to clinical interpretation through qualified medical professional or referring physician. Further clinically interpretative support, if sought, shall be provided in medically valid scenarios to registered medical practitioners only. Laboratory results must be interpreted with objective clinical judgment, in conjunction with clinical presentation, history, and other diagnostic evidence. TATA Imglabs shall not be liable to any subjective interpretative litigations or any claim pertaining to its tested results. All laboratory analysis, interpretations and reporting are performed in the presumption of data provided along with the test specimen. Any demographic amendment requested after generation of the lab report is subject to verification of the same by the lab depending upon evidence provided by the patient/client. Specified biological reference ranges encompass 95% confidence limits of a given population, hence there is a possibility that an otherwise normal/healthy individual shows certain test results that may fall in the abnormal range. This report is not subject to use for any medico-legal purpose. Test results depend upon the quality of sample as well as assay procedure & may vary from lab to lab and also from time to time for the same parameters for the same patient. In case of unexpected abnormality in the lab results, TATA Imglabs may be contacted for repeat analysis which would be performed if possible after due investigation. Criteria for storage of tested specimen/slides/histology blocks are in accordance to accreditation guidelines. A requested test may not be carried out under circumstances of sample insufficiency, loss of sample integrity, availability of insufficient clinical and demographic information, specimen identification issues or withdrawal of request. Neither TATA Imglabs Pvt.Ltd. nor its directors/employees/representatives would be liable to any claims for damage that may be incurred by any person including the patient, as a result of assumptions from lab reports. Financial or monetary claims are subject to approval from the management and shall not exceed the stipulated test cost under any circumstances. All claims are subject to the jurisdiction of Delhi, India. There may be circumstances beyond our control that might delay test results. TATA Imglabs outsources certain tests to other labs for providing a wider test menu to its clients under one umbrella. The details of the laboratory where a sample was referred to, can be obtained from the Customer care help-desk Tel No 0124-4166666